Dr. Reddy’s Laboratories Limited (NYSE:RDY) Stock Holdings Lifted by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC grew its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 400.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 534,304 shares of the company’s stock after acquiring an additional 427,573 shares during the period. Allspring Global Investments Holdings LLC owned 0.06% of Dr. Reddy’s Laboratories worth $8,373,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RDY. Robeco Institutional Asset Management B.V. increased its holdings in shares of Dr. Reddy’s Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock worth $180,620,000 after purchasing an additional 9,373,412 shares during the period. Artemis Investment Management LLP increased its stake in Dr. Reddy’s Laboratories by 398.3% during the fourth quarter. Artemis Investment Management LLP now owns 295,530 shares of the company’s stock valued at $4,666,000 after acquiring an additional 236,224 shares during the period. Augustine Asset Management Inc. lifted its position in Dr. Reddy’s Laboratories by 392.6% in the fourth quarter. Augustine Asset Management Inc. now owns 249,744 shares of the company’s stock worth $3,943,000 after purchasing an additional 199,044 shares during the period. Fisher Asset Management LLC increased its position in shares of Dr. Reddy’s Laboratories by 59.4% during the 3rd quarter. Fisher Asset Management LLC now owns 491,303 shares of the company’s stock worth $39,034,000 after purchasing an additional 183,146 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Dr. Reddy’s Laboratories by 219.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 155,481 shares of the company’s stock valued at $12,353,000 after buying an additional 106,796 shares in the last quarter. Institutional investors and hedge funds own 3.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on RDY shares. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Barclays decreased their price target on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. Finally, Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Stock Down 0.3 %

Dr. Reddy’s Laboratories stock opened at $13.57 on Wednesday. The company has a 50 day moving average of $14.71 and a 200-day moving average of $15.26. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a twelve month low of $13.36 and a twelve month high of $16.89. The stock has a market capitalization of $11.32 billion, a PE ratio of 21.60 and a beta of 0.50.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, equities research analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.